Yessica Dianet Nahuelpán Ferrada

Mrs. Yessica Dianet Nahuelpán Ferrada


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2025 in Cells
Verified
Journal Article
Open access
PDF file
DCDiego Carrillo-Beltrán
Diego Carrillo-Beltrán
YFYessica Dianet Nahuelpán Ferrada
Yessica Dianet Nahuelpán Ferrada
CCConstanza Cuevas
Constanza Cuevas
KFKaren Fabres
Karen Fabres
PSPamela Silva
Pamela Silva
CQClaudia Quezada
Claudia Quezada
Glioblastoma (GB) is a highly malignant brain tumor with a poor prognosis, with a median survival of only 14.6 months despite aggressive treatments. Resistance to chemotherapy, particularly temozolomide (TMZ), is a significant challenge. The DNA repair enzyme MGMT and glioblastoma stem cells (GSCs) often mediate this resistance. Recent studies highlight the therapeutic potential of natural compounds, particularly delphinidins, found in deep purple berries. Delphinidins are known for their ability to inhibit NF-κB signaling, a critical pathway for GB progression, chemoresistance, and MGMT expression. Our research demonstrates that glycosylated delphinidins have potential adjuvant use in the treatment of GB, offering a promising natural strategy to combat TMZ resistance. Specifically, we observed that delphinidin 3,5 di-glucoside has potent anticancer effects when used alone. Meanwhile, delphinidin 3 glucoside acted in synergy with temozolomide to decrease cell viability, highlighting its potential as an adjuvant. It also exerted a faster and more sustained inhibition of NF-κB, highlighting its potential for long-lasting therapeutic effects. These findings open new avenues for targeted therapies against glioblastoma, particularly to overcome treatment resistance.

12 June 2025 in Cells
Verified
Journal Article
Open access
PDF file
IAIgnacio Arias
Ignacio Arias
CJClaudia Jara
Claudia Jara
PMPablo Alexis Mendoza-Soto
Pablo Alexis Mendoza-Soto
YFYessica Dianet Nahuelpán Ferrada
Yessica Dianet Nahuelpán Ferrada
CCClaudio Cappelli
Claudio Cappelli
RMRody San Martin
Rody San Martin
Studies have emphasized alleviating fibrogenesis through interference with adenosine signaling in experimental diabetic nephropathy. We found that the in vivo antagonism of the adenosine A2B receptor (A2BAR) using MRS1754 in diabetic rats impedes the diabetes-induced glomerular expression of the mesenchymal-like transformation markers Snail and α-SMA, while the loss of the epithelial podocyte-specific proteins nephrin and ZO-1 was prevented. Furthermore, the production of MCP-1, CCL3, TGF-β, and the transcript levels of inflammatory mediators was reduced by A2BAR antagonism. Using human podocytes in vitro, we demonstrated that A2BAR antagonism affected the TGF-β-induced activation of SMAD2/-3, as evidenced by the attenuated phosphorylation of SMAD2/-3 and decreased SMAD3 occupancy at target gene promoters following the MRS1754 treatment. Moreover, the non-canonical activation of p65-NF-κB, the primary inflammatory signaling pathway downstream of TGF-β, and the expression of Snail were also reduced by MRS1754. We conclude that an A2BAR blockade interferes with the pathogenic TGF-β signaling cascade responsible for the phenotypical transformation of podocytes, thereby alleviating diabetic glomerulopathy.